European Sold Production of Blood-Grouping Reagents by Country, 2023 Discover more data with ReportLinker!

Global Blood Grouping Reagents Market Size Value by Country, 2023 Discover more data with ReportLinker!

This statistic displays the number of individuals active on the kidney-only transplant waiting list in Eurotransplant countries in 2024, by blood group. In this year, around *** thousand individuals on the kidney transplant waiting list had the blood group O.

Percentages of blood groups (fi), susceptibility, , and inverse characteristic time, m, of the exponential phase of the infection for the analyzed countries as derived for the fit to the observed data.

Blood Group Typing Market Outlook

The global blood group typing market size was valued at approximately USD 2.1 billion in 2023 and is projected to reach around USD 3.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period. This significant growth can be attributed to the increasing demand for safe blood transfusion, rising prevalence of chronic diseases, and advancements in technology related to blood group typing methodologies.

One of the primary growth factors of the blood group typing market is the rising incidence of chronic diseases and medical conditions that necessitate blood transfusion. Diseases such as cancer, hemophilia, and trauma cases require precise blood typing to ensure patient safety during transfusions. Furthermore, the growing number of surgical procedures, which often require blood transfusions, is another driving factor. The increasing adoption of blood group typing in prenatal screenings to prevent hemolytic disease in newborns is also contributing significantly to the market growth.

The advancements in technology are playing a crucial role in the blood group typing market. New methodologies such as polymerase chain reaction (PCR)-based techniques, microarray, and massively parallel sequencing have revolutionized the accuracy and efficiency of blood typing. These technological advancements reduce the risk of transfusion-related complications and improve patient outcomes. Moreover, the integration of artificial intelligence and machine learning in diagnostic processes is further enhancing the accuracy and speed of blood group typing, thereby fueling market growth.

Another critical factor contributing to the market growth is the increasing awareness and governmental initiatives promoting voluntary blood donation. Governments and NGOs are undertaking various programs to educate the public about the importance of blood donation and the need for safe transfusion practices. These initiatives are resulting in increased blood donation rates, which in turn is driving the demand for advanced blood group typing techniques. Additionally, the rising healthcare expenditure in developing countries is enabling the adoption of sophisticated blood typing technologies, further propelling market growth.

Regionally, North America is expected to hold the largest market share due to the high prevalence of chronic diseases, advanced healthcare infrastructure, and significant investment in research and development. Europe is also anticipated to witness substantial growth owing to the increasing number of blood donations and advancements in healthcare technology. The Asia Pacific region is projected to experience the highest growth rate, driven by the large population base, increasing awareness about blood donation, and improving healthcare facilities. Latin America and the Middle East & Africa are also poised for growth, albeit at a slower pace, due to ongoing development in healthcare infrastructure and rising awareness.

Product Analysis

The product segment of the blood group typing market is categorized into instruments and reagents & kits. Instruments include automated and semi-automated analyzers used in blood typing, while reagents & kits encompass various antibodies, antigen kits, and other consumables necessary for blood typing procedures. The demand for instruments is driven by the need for high-throughput and accurate testing in hospitals and diagnostic laboratories. Automated analyzers are particularly gaining traction due to their ability to process large volumes of samples efficiently and with precision.

Reagents & kits hold a significant share in the market due to their recurring demand in routine blood typing tests. Continuous advancements and innovations in reagents, such as the development of monoclonal antibodies, are enhancing the accuracy and reliability of blood typing tests. The availability of a wide range of reagent kits designed for various blood typing techniques, including PCR-based and microarray methods, is further driving the market growth. Additionally, the increasing use of reagents in research laboratories for developing new blood typing methodologies is contributing to the segment's expansion.

The instruments segment is anticipated to witness considerable growth during the forecast period, driven by technological advancements and the rising adoption of automated systems in healthcare settings. The integration of advanced software and artificial intelligence in these instruments is further improving their efficiency and accura

China Export: Blood-grouping Reagent data was reported at 64,979.000 kg in Dec 2021. This records an increase from the previous number of 63,722.000 kg for Nov 2021. China Export: Blood-grouping Reagent data is updated monthly, averaging 19,771.000 kg from Jan 2003 (Median) to Dec 2021, with 228 observations. The data reached an all-time high of 148,026.000 kg in Jun 2017 and a record low of 0.000 kg in Mar 2010. China Export: Blood-grouping Reagent data remains active status in CEIC and is reported by General Administration of Customs. The data is categorized under Global Database’s China – Table CN.RTB: Pharmaceutical Trade: Diagnosis and Treatment Appliances: Quantity.

Global Export of Blood-Grouping Reagents by Country, 2023 Discover more data with ReportLinker!

Brazil Imports: NCM: fob: Reagents Fordetermination of The Blood-Grouping data was reported at 0.905 USD mn in Mar 2025. This records an increase from the previous number of 0.698 USD mn for Feb 2025. Brazil Imports: NCM: fob: Reagents Fordetermination of The Blood-Grouping data is updated monthly, averaging 0.624 USD mn from Apr 2022 (Median) to Mar 2025, with 36 observations. The data reached an all-time high of 0.952 USD mn in Feb 2024 and a record low of 0.392 USD mn in Aug 2022. Brazil Imports: NCM: fob: Reagents Fordetermination of The Blood-Grouping data remains active status in CEIC and is reported by Special Secretariat for Foreign Trade and International Affairs. The data is categorized under Brazil Premium Database’s Foreign Trade – Table BR.NCM: HS38: Miscellaneous Chemical Products: Imports: Value.

Blood Grouping Reagent Market Outlook

The global blood grouping reagent market size is projected to grow from $1.2 billion in 2023 to $2.1 billion by 2032, reflecting a compound annual growth rate (CAGR) of 6.5%. The market's growth is primarily driven by the increasing demand for blood transfusions and the growing awareness about blood safety. Additionally, the rise in the global prevalence of chronic diseases necessitates regular blood tests and transfusions, further fueling the market's expansion.

One of the key growth factors in the blood grouping reagent market is the rising incidence of road accidents and trauma cases which require urgent blood transfusions. This situation is particularly prevalent in developing countries where road safety measures may not be as stringent. Consequently, the demand for accurate and efficient blood grouping reagents is critical in ensuring that these transfusions are safe and effective. Furthermore, advancements in medical technology have led to the development of more sophisticated and reliable blood grouping reagents, which has increased their adoption in various healthcare settings.

The aging population is another significant factor contributing to the growth of the blood grouping reagent market. As the global demographic trend shifts towards an older population, the incidence of age-related conditions such as anemia, cancer, and cardiovascular diseases is on the rise. These conditions often require regular blood transfusions and, consequently, a greater need for blood grouping reagents. This demographic shift is particularly notable in regions such as North America and Europe, further driving the market in these areas.

Moreover, the increasing number of surgical procedures globally is also boosting the demand for blood grouping reagents. Elective surgeries, organ transplants, and other complex medical procedures often necessitate the use of precise blood grouping reagents to ensure compatibility between donor and recipient blood. The growing healthcare infrastructure in emerging economies, coupled with increased healthcare spending, is expected to further augment the demand for these reagents. Additionally, government initiatives and funding for the establishment and maintenance of blood banks and transfusion centers are playing a vital role in propelling market growth.

From a regional perspective, the Asia Pacific region is anticipated to witness the highest growth rate in the blood grouping reagent market during the forecast period. This growth can be attributed to the expanding healthcare sector, rising population, and increasing prevalence of chronic diseases in countries such as China and India. Furthermore, ongoing investments in healthcare infrastructure and technological advancements in diagnostic techniques are expected to enhance the market's growth in this region. Conversely, developed regions like North America and Europe will continue to dominate the market due to their well-established healthcare systems and high awareness about blood safety.

In the realm of blood grouping reagents, the Haptoglobin Reagent has emerged as a crucial component in enhancing diagnostic accuracy. This reagent is particularly significant in the context of hemolysis detection, where it aids in identifying free hemoglobin levels in the blood. The application of Haptoglobin Reagent is not limited to routine diagnostics; it extends to research settings where precise hemoglobin quantification is essential. As the demand for more refined blood testing methods grows, the role of such reagents becomes increasingly pivotal. Their integration into existing diagnostic frameworks can lead to more comprehensive patient assessments, ultimately contributing to better healthcare outcomes.

Product Type Analysis

The blood grouping reagent market by product type encompasses Anti-A Reagents, Anti-B Reagents, Anti-AB Reagents, Anti-D Reagents, and others. Each of these reagents plays a crucial role in identifying specific antigens on red blood cells, which is essential for determining blood compatibility. Anti-A reagents are used to detect the presence of A antigens, while Anti-B reagents are used for B antigens. Anti-AB reagents can identify both A and B antigens, and Anti-D reagents are used to determine the presence of the Rh factor, which is critical in preventing hemolytic disease in newborns.

Anti-A and Anti-B reagents constitute a significant portion of the market du

When according to the numbers of Wikipedia (although they are disputed) in countries like Chile, Ecuador, Colombia, Simbabwe and Mexico 59 to 85 percent of the people have blood group O and these countries officially publish extremely low COVID-19 cases and death rates per 1 million inhabitants, this may not alone result from insufficient investigations but might suggest a lower susceptibility of blood group O to the disease. The molecular biology of a virus infection pathogenesis determines the genetic target and the human phenotype-determining enzymes decide about the difference between infection and disease. In the case that O-glycosylation plays a key role in the pathogenesis of coronavirus infections, as was discussed already 14 years ago in a SARS-CoV virus infection and is currently again predicted for SARS-CoV-2 or COVID-19, this would involve the formation of hybrid, serologically A-like, O-GalNAcα1-Ser/Thr-R, Tn (“T nouvelle”) antigenic structures. Although the ACE2 (angiotensin-converting-enzyme 2) protein is defined as the primary SARS-CoV receptor, it is the history of the amino acid serine, suggesting the actual or additional binding via an intermediate hybrid O-glycan: the protease-mobilized, virus-encoded serine molecule gets access to the host's N-acetyl-D-galactosamine (GalNAc) metabolism and the resulting intermediate, hybrid A-like/Tn structure performs the adhesion of the virus to host cells primarily independent of the ABO blood group, while the phenotype-determining sugars become the final glycosidic target. Individuals with blood group A cannot respond with either acquired or innate antibodies to the synthesis of A-like hybrid structures due to clonal selection and phenotypic accommodation of plasma proteins but perform a further (blood group-A-specific) hybrid binding. A first statistical study suggests that people with blood group A have a significantly higher risk for acquiring COVID-19, whereas people with blood group O have a significantly lower risk for the infection compared with non-O blood groups (Zhao, J. et al., 2020). While these findings await confirmations, blood group O individuals, lacking the blood group-A-determining enzyme, may develop the least molecular contact with the virus and maintain the anti-A/Tn cross-reactive, complement-dependent isoagglutinin activity, which is exerted by the polyreactive, nonimmune immunoglobulin M (IgM), representing the humoral spearhead of innate immunity and a first line of defense.Reference: Zhao, J. et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. medRxiv (2020) doi:10.1101/2020.03.11.20031096.

China Import: HS 8: Blood-Grouping Reagents data was reported at 35.148 RMB mn in Dec 2021. This records a decrease from the previous number of 40.423 RMB mn for Nov 2021. China Import: HS 8: Blood-Grouping Reagents data is updated monthly, averaging 28.471 RMB mn from Jan 2015 (Median) to Dec 2021, with 84 observations. The data reached an all-time high of 52.082 RMB mn in Aug 2020 and a record low of 5.818 RMB mn in Feb 2016. China Import: HS 8: Blood-Grouping Reagents data remains active status in CEIC and is reported by General Administration of Customs. The data is categorized under China Premium Database’s International Trade – Table CN.JKF: RMB: HS30: Pharmaceutical Products.

Global trade data of Blood grouping under 3002903000, 3002903000 global trade data, trade data of Blood grouping from 80+ Countries.

China Import: HS 8: for Blood-Grouping data was reported at 30.832 RMB mn in Mar 2025. This records an increase from the previous number of 11.460 RMB mn for Feb 2025. China Import: HS 8: for Blood-Grouping data is updated monthly, averaging 27.621 RMB mn from Jan 2022 (Median) to Mar 2025, with 39 observations. The data reached an all-time high of 48.370 RMB mn in Sep 2023 and a record low of 11.460 RMB mn in Feb 2025. China Import: HS 8: for Blood-Grouping data remains active status in CEIC and is reported by General Administration of Customs. The data is categorized under China Premium Database’s International Trade – Table CN.JKF: RMB: HS38: Miscellaneous Chemical Products.

This Eurobarometer survey includes questions on behaviours and attitudes in relation to organ donation and transplantation. It is based on a Eurobarometer survey of 26,788 European citizens carried out in October 2009 in the 27 European Union Member States, as well as 3,504 interviews in the candidate countries (Croatia, Turkey and the Former Yugoslav Republic of Macedonia) and the Turkish Cypriot Community.

The results by volumes are distributed as follows:

• Volume A: Countries
• Volume AA: Groups of countries
• Volume A' (AP): Trends
• Volume AA' (AAP): Trends of groups of countries
• Volume B: EU/socio-demographics
• Volume B' (BP) : Trends of EU/ socio-demographics
• Volume C: Country/socio-demographics ---- Researchers may also contact GESIS - Leibniz Institute for the Social Sciences: https://www.gesis.org/eurobarometer

In 2020, close to *** million bags of blood components were distributed in Brazil out of five million bags produced, most of which were accounted for by packed red blood cells (PRBCs). That year, over *** million bags of PRBCs were distributed in the country. In comparison, white blood cells (WBCs) accounted for approximately ***** bags.

In 2018, it was estimated that high-income countries accounted for ** percent of blood donations worldwide, although high-income countries represent just ** percent of the world population. This statistic shows the distribution of blood donations worldwide compared to population distribution in 2018, by income group.

China Import: Blood-grouping Reagent data was reported at 28,212.000 kg in Dec 2021. This records a decrease from the previous number of 41,020.000 kg for Nov 2021. China Import: Blood-grouping Reagent data is updated monthly, averaging 5,257.500 kg from Jan 2003 (Median) to Dec 2021, with 228 observations. The data reached an all-time high of 45,068.000 kg in Sep 2020 and a record low of 57.000 kg in May 2004. China Import: Blood-grouping Reagent data remains active status in CEIC and is reported by General Administration of Customs. The data is categorized under Global Database’s China – Table CN.RTB: Pharmaceutical Trade: Diagnosis and Treatment Appliances: Quantity.

India Imports: Volume: HS: 30062000: Blood-Grouping Reagents data was reported at 14.440 kg th in 2018. This records an increase from the previous number of 2.370 kg th for 2017. India Imports: Volume: HS: 30062000: Blood-Grouping Reagents data is updated yearly, averaging 13.305 kg th from Mar 1997 (Median) to 2018, with 22 observations. The data reached an all-time high of 21.540 kg th in 2009 and a record low of 2.340 kg th in 1997. India Imports: Volume: HS: 30062000: Blood-Grouping Reagents data remains active status in CEIC and is reported by Ministry of Commerce and Industry. The data is categorized under India Premium Database’s Foreign Trade – Table IN.JBG006: Foreign Trade: Harmonized System 8 Digits: By Commodity: HS30: Pharmaceutical Products: Imports: Volume.

The objective of this Special Eurobarometer report is to understand European citizens’ behaviour and attitudes towards donating and receiving treatment with these body substances (excluding solid organs). This will help to shape future policy for donors and recipients. The survey begins, setting the context for the topic, by establishing respondents’ experiences of donating specific body substances. It then moves on to establish attitudes to donating, either while alive or after death. Finally, the survey considers respondents’ attitudes to receiving treatment with donated body substances and the need for legislation at EU-level. This report includes a breakdown by country. It also provides detailed socio-demographic information including gender, age and education and where appropriate looks at data for the relevant age groups for each type of tissue donation. #####The results by volumes are distributed as follows: * Volume A: Countries * Volume AA: Groups of countries * Volume A' (AP): Trends * Volume AA' (AAP): Trends of groups of countries * Volume B: EU/socio-demographics * Volume C: Country/socio-demographics ---- Researchers may also contact GESIS - Leibniz Institute for the Social Sciences: http://www.gesis.org/en/home/